Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Multimorbidity and functional capacity in old age
Clarify individual health status and reduce risks
- Tick season: danger from early summer meningoencephalitis
TBE vaccination recommended for adults and children aged 3 and over
- New WHO guideline, updated stimulation protocols, focus on PGT-A
Fertility and reproductive medicine 2026
- Wound treatment
Surgical wound complications
- Proteins in wound healing
Do special amino acids lead to success?
- Proteins in wound healing
Do special amino acids lead to success?
- Psychedelic-assisted therapy
Current status of PAT
- Hepatitis B prophylaxis